Compare STEM & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STEM | GRML |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6M | 29.2M |
| IPO Year | 2020 | 2022 |
| Metric | STEM | GRML |
|---|---|---|
| Price | $2.38 | $3.82 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $6.25 | N/A |
| AVG Volume (30 Days) | 165.5K | ★ 2.8M |
| Earning Date | 11-05-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.25 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $156,266,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.96 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 8.08 | N/A |
| 52 Week Low | $2.15 | $0.16 |
| 52 Week High | $22.12 | $18.21 |
| Indicator | STEM | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 25.49 | 37.70 |
| Support Level | N/A | $0.28 |
| Resistance Level | $6.02 | $7.53 |
| Average True Range (ATR) | 0.30 | 0.64 |
| MACD | -0.08 | -0.29 |
| Stochastic Oscillator | 13.14 | 1.36 |
Stem Inc is a provider of energy storage systems. The company bundles third-party hardware with its proprietary Athena software to provide customers a turnkey solution. Stem sells its solutions to commercial and industrial customers as well as independent power producers and renewable developers. Its solutions help customers maximize renewable energy generation and help build a cleaner and more resilient grid. The Company operates as one operating segment that is focused exclusively on technology services that transform the way energy is distributed and consumed.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.